Piper Sandler Downgrades CONMED (CNMD) to Neutral

March 17, 2026 3:39 AM

Piper Sandler analyst Matt O'Brien downgraded CONMED (NYSE: CNMD) from Overweight to Neutral with a price target of $39.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found